Bristol-Myers Squibb Co (NYSE: BMY) started the day on Wednesday, with a price increase of 0.08% at $59.60, before settling in for the price of $59.55 at the close. Taking a more long-term approach, BMY posted a 52-week range of $39.35-$63.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 15.21%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 485.76%. This publicly-traded company’s shares outstanding now amounts to $2.03 billion, simultaneously with a float of $2.03 billion. The organization now has a market capitalization sitting at $121.27 billion. At the time of writing, stock’s 50-day Moving Average stood at $58.80, while the 200-day Moving Average is $53.05.
Bristol-Myers Squibb Co (BMY) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Drug Manufacturers – General Industry. Bristol-Myers Squibb Co’s current insider ownership accounts for 0.08%, in contrast to 79.73% institutional ownership. According to the most recent insider trade that took place on Feb 20 ’25, this organization’s Chief Executive Officer bought 2,000 shares at the rate of 55.05, making the entire transaction reach 110,096 in total value, affecting insider ownership by 104,626. Preceding that transaction, on Feb 14 ’25, Company’s EVP,Chief Med.Offr.,Drug Dev. bought 1,823 for 54.84, making the whole transaction’s value amount to 100,000. This particular insider is now the holder of 63,932 in total.
Bristol-Myers Squibb Co (BMY) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.7 per share during the current fiscal year.
Bristol-Myers Squibb Co’s EPS increase for this current 12-month fiscal period is 485.76% and is forecasted to reach 6.12 in the upcoming year.
Bristol-Myers Squibb Co (NYSE: BMY) Trading Performance Indicators
Let’s observe the current performance indicators for Bristol-Myers Squibb Co (BMY). It’s Quick Ratio in the last reported quarter now stands at 1.15. The Stock has managed to achieve an average true range (ATR) of 1.54. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.51. Similarly, its price to free cash flow for trailing twelve months is now 8.70.
In the same vein, BMY’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -4.43, a figure that is expected to reach 1.52 in the next quarter, and analysts are predicting that it will be 6.12 at the market close of one year from today.
Technical Analysis of Bristol-Myers Squibb Co (BMY)
If we take a close look at the recent performances of Bristol-Myers Squibb Co (NYSE: BMY), its last 5-days Average volume was 9.82 million that shows plunge from its year to date volume of 11.6 million. During the previous 9 days, stock’s Stochastic %D was recorded 53.27% While, its Average True Range was 1.55.
Raw Stochastic average of Bristol-Myers Squibb Co (BMY) in the period of the previous 100 days is set at 61.90%, which indicates a major rise in contrast to 40.18% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 23.39% that was lower than 29.20% volatility it exhibited in the past 100-days period.
